Heat Biologics, Inc. (HTBX) Trading Up -0.4%
Heat Biologics, Inc. (NASDAQ:HTBX)’s share price was up 0.4% during trading on Friday . The company traded as high as $0.57 and last traded at $0.56, with a volume of 118,176 shares. The stock had previously closed at $0.56.
A number of equities analysts recently commented on HTBX shares. Zacks Investment Research cut shares of Heat Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 30th. Noble Financial reaffirmed a “buy” rating on shares of Heat Biologics in a research note on Sunday, May 14th. Finally, ValuEngine cut shares of Heat Biologics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th.
The company’s market capitalization is $19.68 million. The stock’s 50 day moving average is $0.51 and its 200-day moving average is $0.70.
Several large investors have recently made changes to their positions in HTBX. KCG Holdings Inc. boosted its stake in shares of Heat Biologics by 35.3% in the first quarter. KCG Holdings Inc. now owns 175,769 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 45,831 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Heat Biologics by 11.9% in the second quarter. Vanguard Group Inc. now owns 661,388 shares of the biopharmaceutical company’s stock worth $403,000 after buying an additional 70,290 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in shares of Heat Biologics during the first quarter worth $2,176,000. Institutional investors and hedge funds own 8.74% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.